C WorldWide Group Holding A S raised its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 18.5% during the second quarter, Holdings Channel reports. The institutional investor owned 96,600 shares of the biotechnology company’s stock after buying an additional 15,100 shares during the period. C WorldWide Group Holding A S’s holdings in Aclaris Therapeutics were worth $2,620,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Aclaris Therapeutics by 269.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,801 shares of the biotechnology company’s stock worth $143,000 after buying an additional 3,500 shares in the last quarter. Falcon Point Capital LLC raised its stake in Aclaris Therapeutics by 65.5% in the first quarter. Falcon Point Capital LLC now owns 13,546 shares of the biotechnology company’s stock worth $404,000 after buying an additional 5,363 shares in the last quarter. Wells Fargo & Company MN raised its stake in Aclaris Therapeutics by 91.3% in the first quarter. Wells Fargo & Company MN now owns 12,359 shares of the biotechnology company’s stock worth $369,000 after buying an additional 5,900 shares in the last quarter. Strs Ohio acquired a new stake in Aclaris Therapeutics during the first quarter worth approximately $629,000. Finally, First Mercantile Trust Co. raised its stake in Aclaris Therapeutics by 11.2% in the first quarter. First Mercantile Trust Co. now owns 5,945 shares of the biotechnology company’s stock worth $177,000 after buying an additional 600 shares in the last quarter. 88.64% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics, Inc. (NASDAQ ACRS) opened at 25.08 on Friday. The stock has a 50 day moving average of $27.77 and a 200 day moving average of $27.95. The firm’s market cap is $670.54 million. Aclaris Therapeutics, Inc. has a one year low of $19.30 and a one year high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. Equities research analysts predict that Aclaris Therapeutics, Inc. will post ($3.10) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “C WorldWide Group Holding A S Has $2.62 Million Stake in Aclaris Therapeutics, Inc. (ACRS)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.watchlistnews.com/c-worldwide-group-holding-a-s-has-2-62-million-stake-in-aclaris-therapeutics-inc-acrs/1478010.html.

A number of research firms have commented on ACRS. Jefferies Group LLC set a $36.00 target price on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a report on Thursday, April 20th. BidaskClub raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 24th. Guggenheim reaffirmed a “buy” rating and set a $40.00 target price on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday. Finally, Zacks Investment Research lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 12th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Aclaris Therapeutics currently has an average rating of “Hold” and a consensus price target of $39.00.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.